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20 Oral Presentationsand 13.2 cGy TBI. GVHD prophylaxis was with CSA/MMF.
Thirty two percent were transplanted with one UCB unit and
68% with two units. Disease status at the time of transplant in-
cluded: CR1 (46%), CR2 (45%), .CR2-relapse (9%). Sixty one
percent of patients are alive at a median follow up of 737 days
(range 44–2,322 days). Using survival tree and log rank analysis,
weekly ALCs were analyzed to determine an ALC cut-point which
gave two distinct groups based on transplant associated outcomes.
In multivariate analysis an ALC . 0.2  109/L at 4 weeks after
UCB transplant was associated with significantly better disease
free survival (DFS) (relative risk (RR) 5 0.158, 69% vs. 33%,
p 5 0.0005) and overall survival (OS) at 2 years (RR 5 0.125,
74% vs. 33%, p\0.0001). Similarly, at this same cut off (ALC .
0.2), patients were less likely to have treatment related mortality
(TRM) (RR 5 0.01, 7% vs. 67%, p\0.0001). For grade II-IV
aGVHD, multivariate analysis showed that an ALC . 0.4 (at 4
weeks post-transplant) was associated with less aGVHD at
D1100 (RR 5 0.057, 28% vs. 61%, p 5 0.0004). At 7 weeks after
transplant, patients with an ALC . 1.2 109/liter was associated
with a lower risk of relapse (univariate analysis 0% vs. 21%, p 5
0.026). We next sought to determine whether any factor predicted
better ALC recovery at four weeks post-UCB transplant. Multi-
variate analysis revealed that the only factor associated with
more rapid ALC recovery was the use of two umbilical cord blood
units. Double unit recipients had an ALC that was10.155 109/L
higher at 4 weeks compared to single unit recipients (p 5 0.039).
Collectively, these data suggest that ALC is a readily available
parameter for assessing risks for TRM, DFS, OS and relapse.
Rapid ALC recovery may explain the observed benefits with
double UCB transplant.LATE EFFECTS/QUALITY OF LIFE
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THE IMPACT OF FULL DOSE TOTAL BODY IRRADIATION(TBI)-CONTAIN-
ING CONDITIONING ON CHRONIC KIDNEY DISEASE AND THROMBOTIC
MICROANGIOPATHIC ANEMIA IN ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION(HSCT)
Glezerman, I.1, Jhaveri, K.2, Papadopouolos, E.B.1, Flombaum, C.1,
Jakubowski, A.A.1 1Memorial Sloan Kettering Cancer Center,
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Background: Chronic kidney disease (CKD) and thrombotic mi-
croangiopathy (TMA) are potential late post-transplant complica-
tions in survivors of HSCT. CKD and TMA can have a significant
impact on healthcare costs and quality of life. Both disorders have
been associated with calcineurin inhibitors (CNI), TBI, older age, fe-
male gender, and graft versus host disease (GVHD), however, the
contribution of each of these factors on development of CKD/
TMA has not been well defined. T-cell depletion (TCD) of allografts
as prophylaxis for GvHD has produced similar survival outcomes to
those of conventional HSCTs in appropriately selected patients and
can obviate the need for CNIs. The lack of CNI exposure offers
a unique opportunity to study the role of TBI in the development
of CKD/TMA.
Methods: Between 1/2001 and 1/2005, 102 adult patients re-
ceived TCD myeloablative HSCTs at MSKCC and met inclusion
criteria for this analysis which was approved by the IRB. Thirty-
two patients received a non-TBI containing regimen (group A) and
70 received TBI (1375 cGy without kidney shielding) with chemo-
therapy (group B). Baseline and followup data were collected by a ret-
rospective review of medical records. Renal function (estimated
glomerular filtration rate [GFR]) was calculated using the Modified
Diet in Renal Disease extended equation. TMA was diagnosed by
kidney biopsy or by identification of multiple components of the
clinical syndrome.
Results: Median followup for both groups was 21 months. Results
and incidence of CKD and TMA are summarized below. Of note,
pretransplant GFR was lower in group A vs B (p\0.006). Incidence
of CKD, TMA, and HTN was significantly higher in those patients
receiving TBI (group B).Conclusions: The data demonstrate a strong correlation between
the use of TBI, in the absence of CNIs, and the development of post-
transplant CKD and TMA, suggesting the need for clinical trials to
prevent these complications when using TBI.Group A Group B P\Pre-treatment GFR1 (mean) 87.1 (SD525.6) 102.3 (SD523.9) 0.006
GFR at 6 months (mean) 72.3 (SD521.9) 74.8 (SD522.6) NS (0.6)
GFR at 12 months (mean) 67.2 (SD514.1) 61.6 (SD519.8) NS (0.13)
GFR at 18 months (mean) 67.9 (SD510.2) 59.8 (SD520.5) 0.02
GFR at 24 months (mean) 68.3 (SD512.3) 60.5 (SD522.0) 0.05
TMA2 0 (0%) 11 (15.7%) 0.016
HTN3 2 (6.3%) 18 (25.7%) 0.02
GFR\30 at 24 months 0 (0%) 6 (10.9%) 0.171Glomerular filtration rate.
2Thombotic microangiopathic anemia.
3Hypertension.48
RELAPSE AND MORTALITY IN YOUNG SURVIVORS 2.5 YEARS AFTER AU-
TOLOGOUS AND ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION FOR SOLID ORGAN TUMORS AND MALIGNANT BLOOD
DISORDERS
Hutspardol, S., Shaw, P.J. The Children’s Hospital AtWestmead, Sydney,
New South Wales, Australia
We studied the mortality, relapse and transplant-related compli-
cations of 331 patients (age 6 month–19 years at transplant, median
8 years) with solid organ tumors (91 soft-tissue tumor and 18 brain
tumor) and malignant blood disorders (200 leukemia and 22
lymphoma) after a bone marrow (n 5 265), peripheral blood (n 5
56), and cord blood (n 5 10) hematopoietic stem cell transplant
(HSCT). One hundred and forty-six patients remained relapse-free
for 2.5 or more years after HSCT. Of these, 132 (90%) were alive
at a median follow up time of 10 years (range; 2.5–27.0). Four
(2.7%) relapsed between 2.7 and 13.4 years (median 6.1) after trans-
plant. No patients with hematologic malignancies relapsed after 2.5
years of HSCT. Six patients (4.1%) died of complications related to
the transplant: 3 from chronic pulmonary graft-versus-host disease
and 1 each from presumed busulphan-induced chronic obstructive
lung disease, cardiomyopathy, and non-GVHD interstitial
pulmonary fibrosis. Three patients (2.1%) developed T-cell ALL,
rhabdomyosarcoma and astrocytoma as second malignancies. For
the external cause of death, one died from drug overdose at 5 years
after the transplant. The 5- and 10-year probabilities of overall sur-
vival (from the 2.5-year mark) are 95% and 93% and the 5- and 10-
year probabilities of relapse free survival (from the 2.5-year mark) are
98% and 95%. In multivariate analysis, peripheral blood stem cell
(PBSC) as the source of stem cells and older age at HSCT unfavor-
ably influenced the overall survival. Gender, age at HSCT, type of
malignant disease, low or high risk category for relapse, stem cell
source and TBI were not found to be predictive for relapse free sur-
vival. In conclusion, for young patients with malignancies who were
relapse free 2.5 years after HSCT, the probability of cure was very
high and the long term survival was excellent. Chronic pulmonary
GVHD was the leading cause of late death. Toxicity related to
high intensity chemotherapy and TBI potentially resulted to the
lung toxicity and death in long term survivors.49
MEASURING THE SYMPTOM BURDEN OF ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN PATIENTS WITH AND WITHOUT
ACUTE GRAFT-VERSUS-HOST DISEASE
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Significance: Allogeneic hematopoietic stem cell transplantation
(alloHSCT) is an intensive but potentially curative therapy for
patients with life-threatening illnesses. During alloHSCT, patients
